ARS Pharmaceuticals (SPRY) Net Income (2020 - 2026)

ARS Pharmaceuticals has disclosed Net Income across 7 years of filings, most recently posting -$62.6 million for Q1 2026.

• Net Income for Q1 2026 came in at -$62.6 million, down 68.35% year-over-year; the trailing twelve-month figure through Mar 2026 was -$61.4 million (down 126.83% YoY), and the FY2025 annual result was -$171.3 million, down 2243.1% from the prior year.
• Net Income came in at -$62.6 million for Q1 2026 at ARS Pharmaceuticals, down from $102.0 million in the prior quarter.
• In the past five years, Net Income ranged from a high of $102.0 million in Q4 2025 to a low of -$62.6 million in Q1 2026.
• The 5-year median for Net Income is -$15.4 million (2022), against an average of -$8.7 million.
• Peak annual rise in Net Income reached 397.08% in 2023, while the deepest fall reached 224.76% in 2023.
• ARS Pharmaceuticals' Net Income stood at -$15.4 million in 2022, then jumped by 397.08% to $45.9 million in 2023, then climbed by 2.88% to $47.2 million in 2024, then jumped by 116.1% to $102.0 million in 2025, then slumped by 161.36% to -$62.6 million in 2026.
• The last three Net Income figures came in at -$62.6 million (Q1 2026), $102.0 million (Q4 2025), and -$53.2 million (Q3 2025), per Business Quant data.